Abstract:SESSION TITLE: Chest Infections Posters 10 SESSION TYPE: Original Investigation Posters PRESENTED ON: 10/11/2023 12:00 pm - 12:45 pm PURPOSE: Mycobacterium avium complex lung disease (MACLD) is a serious pulmonary infection that can cause lung damage. Patients with refractory MACLD often still test positive for MAC infection after 6 months on guideline-based therapy. There are limited data on treatment patterns and healthcare resource utilization (HCRU) among patients with refractory MACLD in the US. The objective of this study was to assess HCRU among US patients with potentially refractory MACLD treatment patterns. METHODS: A retrospective study was conducted using managed care claims from the IBM® MarketScan® research database (2014.07-2020.06). Treated MACLD patients were those who received diagnosis and subsequent initial therapy of ≥28 days of concurrent macrolide with at least one other antibiotic (ethambutol, rifamycin, aminoglycoside, fluoroquinolone, oxazolidinone, diarylquinoline). The first 6 months of treatment was defined as the baseline regimen and the possible refractory date was the date 6 months after treatment initiation. Among patients treated for ≥18 months, treatment patterns indicating potentially refractory MACLD were defined as adding new drug classes after the 6-month baseline treatment. The proportion of refractory MACLD patients with hospitalizations (all-cause, respiratory-related, and NTMLD-related) was assessed at 6-month intervals for a total of 2 years after treatment initiation. RESULTS: The study identified 87 patients (7.5% of 1164 patients treated for MACLD) who showed potentially refractory treatment patterns during the 12-month period after the possible refractory date. Mean (SD) age at MACLD diagnosis was 62 (13) years; 70% were female. During the baseline period, 16% had gastroesophageal reflux disease; common pulmonary comorbidities included COPD (32%), bronchiectasis (29%), pneumonia (29%) and asthma (21%). All-cause and respiratory-related hospitalization rates were high (17% and 7%) during the 6-month baseline treatment period and continued to increase over the 2-year follow-up period, reaching 22% and 11% in months 19-24 after treatment initiation despite treatment of at least 18 months. Ethambutol and rifamycin were included in the baseline regimens of 85% and 82% of refractory patients, respectively. Fluoroquinolone was the most commonly added drug (by 77% of patients) in the 12-month post-refractory treatment period, followed by aminoglycoside (9%). CONCLUSIONS: Despite treatment of at least 1.5 years, patients with potentially refractory MACLD showed high hospitalization burden which remained high or increased over a 2-year follow-up period after treatment initiation. CLINICAL IMPLICATIONS: The increase in hospitalization burden observed after the 6-month initial treatment highlights the need for treatment monitoring and improved management among patients with refractory MACLD. DISCLOSURES: Employee relationship with Insmed Pharmaceuticals Please note: 4 years Added 03/24/2023 by Mariam Hassan, source=Web Response, value=Salary No relevant relationships by Matthew Lucci No relevant relationships by Bonny Shah Employee relationship with Insmed Incorporated Please note: Mar 2017 to Present by Ping Wang, value=Salary Employee relationship with Insmed Incorporated Please note: Mar 2017 to Present Added 03/23/2023 by Ping Wang, source=Web Response, value=Stocks No relevant relationships by Emily Welch Research relationship with Insmed Please note: 24 months or more by Kevin Winthrop, value=Consultation fees Research relationship with Paratek Please note: 24 months or more by Kevin Winthrop, value=Consulting fees Research relationship with Redhill Biopharma Please note: 24 months or more by Kevin Winthrop, value=Consultation fees Research relationship with AN2 Please note: 24 months or more by Kevin Winthrop, value=Grant/Research Support Consultant relationship with AN2 Please note: 24 months or more by Kevin Winthrop, value=Consulting fee Consultant relationship with Spero Therapeutics Please note: 24 months or more by Kevin Winthrop, value=Consulting fee

Relationship between clarithromycin MICs and treatment responses in Mycobacterium avium complex pulmonary disease

Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease

Minimum inhibitory concentrations of azithromycin in clinical isolates of Mycobacterium avium complex in Japan

In Vitro Assessment of 17 Antimicrobial Agents Against Clinical Mycobacterium Avium Complex Isolates

[Treatment with clarithromycin of 173 HIV+ patients with disseminated Mycobacterium avium intracellulare infection]

Impact of Different Subspecies on Disease Progression in Initially Untreated Patients with Mycobacterium Avium Complex Lung Disease

Correlation of drug exposure and bacterial susceptibility with treatment response for Mycobacterium avium complex lung disease: protocol for a prospective observational cohort study

Significance of changes in cavity after treatment in Mycobacterium avium complex pulmonary disease

Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis

Difference in Drug Susceptibility Distribution and Clinical Characteristics Between Mycobacterium Avium and Mycobacterium Intracellulare Lung Diseases in Shanghai, China

The role of treatment regimen and duration in treating patients with Mycobacterium avium complex lung disease: a real-world experience and case-control study

Single-cell transcriptomics by clinical course of Mycobacterium avium complex pulmonary disease

Change of erythrocyte sedimentation rate as prognostic biomarker for Mycobacterium avium complex pulmonary disease through anti-mycobacterial treatment

Clarithromycin-susceptibility Genotype Affects the Treatment Outcome of Patients with Lung Disease.

Treatment patterns and health care resource utilization among patients with potentially treatment-refractory mycobacterium avium complex lung disease in the united states

Biofilm Development by Mycobacterium avium Complex Clinical Isolates: Effect of Clarithromycin in Ultrastructure

Intrinsic clarithromycin heteroresistance in Mycobacterium avium

The use of dual β-lactams to restore susceptibility of Mycobacterium avium complex

1866. Can β-lactam Combinations Restore Susceptibility Against Mycobacterium avium Complex: Exploring a New Approach to a “Difficult to Treat” Opportunistic Pathogen

Effect of multidrug therapy on the prognosis of Mycobacterium avium complex pulmonary disease

Variability of macrolide-resistant profile in Mycobacterium avium complex pulmonary disease